Abstract
p53 is a transcription factor central to cellular DNA metabolism that controls cellular responses to DNA damage. p53 activity, finely regulated, integrates the information from several pathways to preserve the cells genetic information. Great attention has been given to the structural determination of p53 domains and its cancerous mutants because 50% of cancer cases present mutations in p53 that hinder its activity resulting in uncontrolled cell reproduction. We enumerate the multiple studies carried to elucidate the structure of p53 domains and we highlight their main findings. The ultimate goal of the reviewed structural efforts is to understand p53 function at atomic level with the aim to overcome cancer by reversing p53 mutant activity to its normal function.
Keywords: p53, transcription factor, transactivation domain, DNA-binding domain, tetramerization domain, regulatory domain, X-ray crystallography, NMR
Current Topics in Medicinal Chemistry
Title: Molecular Architecture of Tumor Suppressor p53
Volume: 8 Issue: 15
Author(s): Hector Viadiu
Affiliation:
Keywords: p53, transcription factor, transactivation domain, DNA-binding domain, tetramerization domain, regulatory domain, X-ray crystallography, NMR
Abstract: p53 is a transcription factor central to cellular DNA metabolism that controls cellular responses to DNA damage. p53 activity, finely regulated, integrates the information from several pathways to preserve the cells genetic information. Great attention has been given to the structural determination of p53 domains and its cancerous mutants because 50% of cancer cases present mutations in p53 that hinder its activity resulting in uncontrolled cell reproduction. We enumerate the multiple studies carried to elucidate the structure of p53 domains and we highlight their main findings. The ultimate goal of the reviewed structural efforts is to understand p53 function at atomic level with the aim to overcome cancer by reversing p53 mutant activity to its normal function.
Export Options
About this article
Cite this article as:
Viadiu Hector, Molecular Architecture of Tumor Suppressor p53, Current Topics in Medicinal Chemistry 2008; 8 (15) . https://dx.doi.org/10.2174/156802608786141160
DOI https://dx.doi.org/10.2174/156802608786141160 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Chymotrypsin Inhibitory Activity of Substituted Oxazolones
Letters in Drug Design & Discovery Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Current Drug Targets microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Potential of Liposomes for Enhancement of Oral Drug Absorption
Current Drug Delivery Newer Approaches to the Discovery of Glitazones
Mini-Reviews in Organic Chemistry New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Current Diabetes Reviews Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Genomic Instability and Carcinogenesis: An Update
Current Genomics Biomarkers for Hepatocellular Apoptosis in the Management of Liver Diseases
Current Pharmaceutical Biotechnology Medium-term Culture of Normal Human Oral Mucosa: A Novel Three-dimensional Model to Study the Effectiveness of Drugs Administration
Current Pharmaceutical Design SiRNA Nanotherapeutics _The Panacea of Diseases?
Current Gene Therapy